Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 50%
Hold 10%
Sell 10%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics is well-positioned for strong growth potential in the future with its innovative surgical robotic systems for minimally invasive urologic surgery. The company has achieved strong sales growth in recent quarters, led by its domestic capital placements and strong procedure growth rates. Additionally, the company's prostate cancer study is enrolling ahead of schedule, which could open up a new market opportunity for the company. While there may be some short-term concerns regarding softer handpiece sales and pricing pressure, the company's strong pipeline and potential for penetration into international markets provide a positive outlook for its stock in the long run.

Bears say

PROCEPT BioRobotics is facing several challenges, including steep financial ramps to meet its guidance, increasing competition in the BPH surgical market, and uncertainty around the shift in handpiece purchasing patterns. Additionally, the company's decision to eliminate bulk discounts could negatively impact revenue in the short term. However, the company's innovative technology and potential for expansion in the BPH market make it a long-term growth opportunity. With a heavily discounted valuation and tomorrow's Investor Day expected to provide more insights, the stock remains a volatile but attractive long-term investment opportunity.

PRCT has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 10 analysts, PRCT has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.